Rhifn ω

Manufactured by R&D Systems

RhIFN-ω is a recombinant human interferon-omega protein. Interferons are a family of cytokines involved in the immune response. RhIFN-ω is a laboratory reagent for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

Rhifn α, by R&D Systems (2 mentions) Maxisorp, by Thermo Fisher Scientific (2 mentions)

2 protocols using rhifn ω

ELISA Detection of IFN-α/ω Autoantibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols

ELISAs were performed as previously described (Puel et al., 2022 (link)). In brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher Scientific) were coated by incubation overnight at 4°C with 2 μg/ml rhIFN-α and rhIFN-ω (R&D Systems). Plates were then washed (PBS/0.005% Tween), blocked by incubation with the same buffer supplemented with 5% nonfat milk powder, washed, and incubated with 1:50 dilutions of plasma samples from the patients or controls for 2 h at room temperature (or with specific mAbs as positive controls). Each sample was tested once. Plates were thoroughly washed. HRP-conjugated Fc-specific IgG fractions from polyclonal goat antiserum against human IgG or IgA (Nordic Immunological Laboratories) were added to a final concentration of 2 μg/ml. Plates were incubated for 1 h at room temperature and washed. Substrate was added and OD was measured.

Zhang Q., Pizzorno A., Miorin L., Bastard P., Gervais A., Le Voyer T., Bizien L., Manry J., Rosain J., Philippot Q., Goavec K., Padey B., Cupic A., Laurent E., Saker K., Vanker M., Särekannu K., García-Salum T., Ferres M., Le Corre N., Sánchez-Céspedes J., Balsera-Manzanero M., Carratala J., Retamar-Gentil P., Abelenda-Alonso G., Valiente A., Tiberghien P., Zins M., Debette S., Meyts I., Haerynck F., Castagnoli R., Notarangelo L.D., Gonzalez-Granado L.I., Dominguez-Pinilla N., Andreakos E., Triantafyllia V., Rodríguez-Gallego C., Solé-Violán J., Ruiz-Hernandez J.J., Rodríguez de Castro F., Ferreres J., Briones M., Wauters J., Vanderbeke L., Feys S., Kuo C.Y., Lei W.T., Ku C.L., Tal G., Etzioni A., Hanna S., Fournet T., Casalegno J.S., Queromes G., Argaud L., Javouhey E., Rosa-Calatrava M., Cordero E., Aydillo T., Medina R.A., Kisand K., Puel A., Jouanguy E., Abel L., Cobat A., Trouillet-Assant S., García-Sastre A, & Casanova J.L. (2022). Autoantibodies against type I IFNs in patients with critical influenza pneumonia. The Journal of Experimental Medicine, 219(11), e20220514.

+ Open protocol

+ Expand

Measuring IFN-α and IFN-ω Autoantibodies

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

ELISA was performed as previously described (Bastard et al., 2020b (link)). In brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher Scientific) were coated by incubation overnight at 4°C with 2 µg/ml rhIFN-α and rhIFN-ω (R&D Systems). Plates were then washed (PBS/0.005% Tween), blocked by incubation with 5% nonfat milk powder in the same buffer, washed again, and incubated with 1:50 dilutions of plasma from the patients or controls for 2 h at room temperature (or with specific mAbs as positive controls). Each sample was tested once. Plates were thoroughly washed. HRP-conjugated Fc-specific (Fc, fragment crystallizable region) IgG fractions from polyclonal goat antiserum against human IgG or IgA (Nordic Immunological Laboratories) were added to a final concentration of 2 µg/ml. Plates were incubated for 1 h at room temperature and washed. Substrate was added, and the OD was measured. A similar protocol was used to test for Abs against 12 subtypes of IFN-α, except that the plates were coated with cytokines from PBL Assay Science (11002-1).

Bastard P., Michailidis E., Hoffmann H.H., Chbihi M., Le Voyer T., Rosain J., Philippot Q., Seeleuthner Y., Gervais A., Materna M., de Oliveira P.M., Maia M.D., Dinis Ano Bom A.P., Azamor T., Araújo da Conceição D., Goudouris E., Homma A., Slesak G., Schäfer J., Pulendran B., Miller J.D., Huits R., Yang R., Rosen L.B., Bizien L., Lorenzo L., Chrabieh M., Erazo L.V., Rozenberg F., Jeljeli M.M., Béziat V., Holland S.M., Cobat A., Notarangelo L.D., Su H.C., Ahmed R., Puel A., Zhang S.Y., Abel L., Seligman S.J., Zhang Q., MacDonald M.R., Jouanguy E., Rice C.M, & Casanova J.L. (2021). Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. The Journal of Experimental Medicine, 218(4), e20202486.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!